RITA (NSC-652287)
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 407174

CAS#: 213261-59-7

Description: RITA, also known as NSC 652287, is an inducer of both DNA-protein and DNA-DNA cross-links with no detectable DNA single-strand breaks. RITA is also an inhibitor of MDM2-p53 interaction by targeting p53 and induces apoptosis in tumor cells.

Chemical Structure

img
RITA (NSC-652287)
CAS# 213261-59-7
Product data Instruction

Theoretical Analysis

MedKoo Cat#: 407174
Name: RITA (NSC-652287)
CAS#: 213261-59-7
Chemical Formula: C14H12O3S2
Exact Mass: 292.02
Molecular Weight: 292.367
Elemental Analysis: C, 57.51; H, 4.14; O, 16.42; S, 21.93

Price and Availability

Size Price Availability Quantity
5mg USD 90 Ready to Ship
10mg USD 150 Ready to ship
25mg USD 250 Ready to ship
50mg USD 450 Ready to ship
100mg USD 750 Ready to ship
200mg USD 1250 Ready to ship
Bulk inquiry

Synonym: NSC-652287; NSC652287; NSC 652287; RITA

IUPAC/Chemical Name: [5-[5-[5-(hydroxymethyl)thiophen-2-yl]furan-2-yl]thiophen-2-yl]methanol

InChi Key: KZENBFUSKMWCJF-UHFFFAOYSA-N

InChi Code: InChI=1S/C14H12O3S2/c15-7-9-1-5-13(18-9)11-3-4-12(17-11)14-6-2-10(8-16)19-14/h1-6,15-16H,7-8H2

SMILES Code: OCC1=CC=C(C2=CC=C(C3=CC=C(CO)S3)O2)S1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:
Product Data
Certificate of Analysis:
View CoA: current batch, Lot#A22M10B12
Safety Data Sheet (SDS):
View Safety Data Sheet (SDS)
Instruction:
View handling instruction
Biological target: RITA is an inhibitor of p53-HDM-2 interaction, binds to p53dN, with a Kd of 1.5 nM, and also induces DNA-DNA cross-links.
In vitro activity: RITA (RBP-J (recombination signal binding protein J)-interacting and tubulin-associated protein) has been identified as a negative modulator of the Notch pathway and as a microtubule-associated protein important for cell migration and invasion. Reference: Cells. 2019 Nov 21;8(12):1484. https://pubmed.ncbi.nlm.nih.gov/31766533/
In vivo activity: In vivo administration of RITA or GANT61 suppressed rhabdomyosarcoma xenograft growth in nude mice; however, co-administration did not further enhance tumor suppression, even though cell proliferation was decreased. RITA was more potent than GANT61 in downregulating HH target gene expression; surprisingly, this suppressive effect was almost completely eliminated when the two drugs were administered together. Reference: Cancer Lett. 2019 Feb 1;442:341-350. https://pubmed.ncbi.nlm.nih.gov/30447254/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 30.0 102.61
DMF:PBS (pH 7.2) (1:1) 0.5 1.71
DMSO 51.8 177.20
Ethanol 5.4 18.60

Preparing Stock Solutions

The following data is based on the product molecular weight 292.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Wildner JM, Friemel A, Jennewein L, Roth S, Ritter A, Schüttler C, Chen Q, Louwen F, Yuan J, Kreis NN. RITA Is Expressed in Trophoblastic Cells and Is Involved in Differentiation Processes of the Placenta. Cells. 2019 Nov 21;8(12):1484. doi: 10.3390/cells8121484. PMID: 31766533; PMCID: PMC6953008. 2. Ristau J, van Hoef V, Peuget S, Zhu J, Guan BJ, Liang S, Hatzoglou M, Topisirovic I, Selivanova G, Larsson O. RITA requires eIF2α-dependent modulation of mRNA translation for its anti-cancer activity. Cell Death Dis. 2019 Nov 7;10(11):845. doi: 10.1038/s41419-019-2074-3. PMID: 31699971; PMCID: PMC6838152. 3. Azatyan A, Gallo-Oller G, Diao Y, Selivanova G, Johnsen JI, Zaphiropoulos PG. RITA downregulates Hedgehog-GLI in medulloblastoma and rhabdomyosarcoma via JNK-dependent but p53-independent mechanism. Cancer Lett. 2019 Feb 1;442:341-350. doi: 10.1016/j.canlet.2018.11.005. Epub 2018 Nov 14. PMID: 30447254. 4. Gottlieb A, Althoff K, Grunewald L, Thor T, Odersky A, Schulte M, Deubzer HE, Heukamp L, Eggert A, Schramm A, Schulte JH, Künkele A. RITA displays anti-tumor activity in medulloblastomas independent of TP53 status. Oncotarget. 2017 Apr 25;8(17):27882-27891. doi: 10.18632/oncotarget.15840. PMID: 28427187; PMCID: PMC5438615.
In vitro protocol: 1. Wildner JM, Friemel A, Jennewein L, Roth S, Ritter A, Schüttler C, Chen Q, Louwen F, Yuan J, Kreis NN. RITA Is Expressed in Trophoblastic Cells and Is Involved in Differentiation Processes of the Placenta. Cells. 2019 Nov 21;8(12):1484. doi: 10.3390/cells8121484. PMID: 31766533; PMCID: PMC6953008. 2. Ristau J, van Hoef V, Peuget S, Zhu J, Guan BJ, Liang S, Hatzoglou M, Topisirovic I, Selivanova G, Larsson O. RITA requires eIF2α-dependent modulation of mRNA translation for its anti-cancer activity. Cell Death Dis. 2019 Nov 7;10(11):845. doi: 10.1038/s41419-019-2074-3. PMID: 31699971; PMCID: PMC6838152.
In vivo protocol: 1. Azatyan A, Gallo-Oller G, Diao Y, Selivanova G, Johnsen JI, Zaphiropoulos PG. RITA downregulates Hedgehog-GLI in medulloblastoma and rhabdomyosarcoma via JNK-dependent but p53-independent mechanism. Cancer Lett. 2019 Feb 1;442:341-350. doi: 10.1016/j.canlet.2018.11.005. Epub 2018 Nov 14. PMID: 30447254. 2. Gottlieb A, Althoff K, Grunewald L, Thor T, Odersky A, Schulte M, Deubzer HE, Heukamp L, Eggert A, Schramm A, Schulte JH, Künkele A. RITA displays anti-tumor activity in medulloblastomas independent of TP53 status. Oncotarget. 2017 Apr 25;8(17):27882-27891. doi: 10.18632/oncotarget.15840. PMID: 28427187; PMCID: PMC5438615.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Xu J, Eriksson SE, Cebula M, Sandalova T, Hedström E, Pader I, Cheng Q, Myers CR, Antholine WE, Nagy P, Hellman U, Selivanova G, Lindqvist Y, Arnér ES. The conserved Trp114 residue of thioredoxin reductase 1 has a redox sensor-like function triggering oligomerization and crosslinking upon oxidative stress related to cell death. Cell Death Dis. 2015 Jan 22;6:e1616. doi: 10.1038/cddis.2014.574. PubMed PMID: 25611390.

2: Chuang HC, Yang LP, Fitzgerald AL, Osman A, Woo SH, Myers JN, Skinner HD. The p53-reactivating small molecule RITA induces senescence in head and neck cancer cells. PLoS One. 2014 Aug 13;9(8):e104821. doi: 10.1371/journal.pone.0104821. eCollection 2014. PubMed PMID: 25119136; PubMed Central PMCID: PMC4132078.

3: Weilbacher A, Gutekunst M, Oren M, Aulitzky WE, van der Kuip H. RITA can induce cell death in p53-defective cells independently of p53 function via activation of JNK/SAPK and p38. Cell Death Dis. 2014 Jul 10;5:e1318. doi: 10.1038/cddis.2014.284. PubMed PMID: 25010984; PubMed Central PMCID: PMC4123078.

4: Di Marzo D, Forte IM, Indovina P, Di Gennaro E, Rizzo V, Giorgi F, Mattioli E, Iannuzzi CA, Budillon A, Giordano A, Pentimalli F. Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma. Cell Cycle. 2014;13(4):652-65. doi: 10.4161/cc.27546. Epub 2013 Dec 17. PubMed PMID: 24345738.

5: Fiorini C, Menegazzi M, Padroni C, Dando I, Dalla Pozza E, Gregorelli A, Costanzo C, Palmieri M, Donadelli M. Autophagy induced by p53-reactivating molecules protects pancreatic cancer cells from apoptosis. Apoptosis. 2013 Mar;18(3):337-46. doi: 10.1007/s10495-012-0790-6. PubMed PMID: 23238993.

6: Lin J, Jin X, Bu Y, Cao D, Zhang N, Li S, Sun Q, Tan C, Gao C, Jiang Y. Efficient synthesis of RITA and its analogues: derivation of analogues with improved antiproliferative activity via modulation of p53/miR-34a pathway. Org Biomol Chem. 2012 Dec 28;10(48):9734-46. doi: 10.1039/c2ob26627j. Epub 2012 Nov 15. PubMed PMID: 23151607.

7: Sorrentino G, Mioni M, Giorgi C, Ruggeri N, Pinton P, Moll U, Mantovani F, Del Sal G. The prolyl-isomerase Pin1 activates the mitochondrial death program of p53. Cell Death Differ. 2013 Feb;20(2):198-208. doi: 10.1038/cdd.2012.112. Epub 2012 Aug 31. PubMed PMID: 22935610; PubMed Central PMCID: PMC3554345.

8: Jones RJ, Bjorklund CC, Baladandayuthapani V, Kuhn DJ, Orlowski RZ. Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA. Mol Cancer Ther. 2012 Oct;11(10):2243-53. doi: 10.1158/1535-7163.MCT-12-0135. Epub 2012 Aug 28. PubMed PMID: 22933706; PubMed Central PMCID: PMC3469746.

9: Nikulenkov F, Spinnler C, Li H, Tonelli C, Shi Y, Turunen M, Kivioja T, Ignatiev I, Kel A, Taipale J, Selivanova G. Insights into p53 transcriptional function via genome-wide chromatin occupancy and gene expression analysis. Cell Death Differ. 2012 Dec;19(12):1992-2002. doi: 10.1038/cdd.2012.89. Epub 2012 Jul 13. PubMed PMID: 22790872; PubMed Central PMCID: PMC3504713.

10: Roh JL, Ko JH, Moon SJ, Ryu CH, Choi JY, Koch WM. The p53-reactivating small-molecule RITA enhances cisplatin-induced cytotoxicity and apoptosis in head and neck cancer. Cancer Lett. 2012 Dec 1;325(1):35-41. doi: 10.1016/j.canlet.2012.05.020. Epub 2012 May 22. PubMed PMID: 22634494.

11: Michaelis M, Rothweiler F, Agha B, Barth S, Voges Y, Löschmann N, von Deimling A, Breitling R, Doerr HW, Rödel F, Speidel D, Cinatl J Jr. Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents. Cell Death Dis. 2012 Apr 5;3:e294. doi: 10.1038/cddis.2012.35. PubMed PMID: 22476102; PubMed Central PMCID: PMC3358013.

12: Di Conza G, Buttarelli M, Monti O, Pellegrino M, Mancini F, Pontecorvi A, Scotlandi K, Moretti F. IGF-1R/MDM2 relationship confers enhanced sensitivity to RITA in Ewing sarcoma cells. Mol Cancer Ther. 2012 Jun;11(6):1247-56. doi: 10.1158/1535-7163.MCT-11-0913. Epub 2012 Mar 28. PubMed PMID: 22461661.

13: Saha MN, Jiang H, Yang Y, Zhu X, Wang X, Schimmer AD, Qiu L, Chang H. Targeting p53 via JNK pathway: a novel role of RITA for apoptotic signaling in multiple myeloma. PLoS One. 2012;7(1):e30215. doi: 10.1371/journal.pone.0030215. Epub 2012 Jan 20. PubMed PMID: 22276160; PubMed Central PMCID: PMC3262803.

14: Ma T, Yamada S, Ichwan SJ, Iseki S, Ohtani K, Otsu M, Ikeda MA. Inability of p53-reactivating compounds Nutlin-3 and RITA to overcome p53 resistance in tumor cells deficient in p53Ser46 phosphorylation. Biochem Biophys Res Commun. 2012 Jan 20;417(3):931-7. doi: 10.1016/j.bbrc.2011.11.161. Epub 2011 Dec 6. PubMed PMID: 22166212.

15: de Lange J, Verlaan-de Vries M, Teunisse AF, Jochemsen AG. Chk2 mediates RITA-induced apoptosis. Cell Death Differ. 2012 Jun;19(6):980-9. doi: 10.1038/cdd.2011.182. Epub 2011 Dec 9. PubMed PMID: 22158418; PubMed Central PMCID: PMC3354051.

16: Li H, Lakshmikanth T, Garofalo C, Enge M, Spinnler C, Anichini A, Szekely L, Kärre K, Carbone E, Selivanova G. Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2. Cell Cycle. 2011 Oct 1;10(19):3346-58. doi: 10.4161/cc.10.19.17630. Epub 2011 Oct 1. PubMed PMID: 21941086.

17: de Lange J, Ly LV, Lodder K, Verlaan-de Vries M, Teunisse AF, Jager MJ, Jochemsen AG. Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma. Oncogene. 2012 Mar 1;31(9):1105-16. doi: 10.1038/onc.2011.309. Epub 2011 Jul 18. PubMed PMID: 21765463.

18: Textor S, Fiegler N, Arnold A, Porgador A, Hofmann TG, Cerwenka A. Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2. Cancer Res. 2011 Sep 15;71(18):5998-6009. doi: 10.1158/0008-5472.CAN-10-3211. Epub 2011 Jul 15. PubMed PMID: 21764762.

19: Ahmed A, Yang J, Maya-Mendoza A, Jackson DA, Ashcroft M. Pharmacological activation of a novel p53-dependent S-phase checkpoint involving CHK-1. Cell Death Dis. 2011 May 19;2:e160. doi: 10.1038/cddis.2011.42. PubMed PMID: 21593792; PubMed Central PMCID: PMC3122121.

20: Spinnler C, Hedström E, Li H, de Lange J, Nikulenkov F, Teunisse AF, Verlaan-de Vries M, Grinkevich V, Jochemsen AG, Selivanova G. Abrogation of Wip1 expression by RITA-activated p53 potentiates apoptosis induction via activation of ATM and inhibition of HdmX. Cell Death Differ. 2011 Nov;18(11):1736-45. doi: 10.1038/cdd.2011.45. Epub 2011 May 6. PubMed PMID: 21546907; PubMed Central PMCID: PMC3190111.